SLC10A2 and metabolic syndrome: This is the case with FXR agonists47, new peroxisome proliferator-activated receptor (PPAR)-gamma or PPAR-alpha modulators48,49, GIP/GLP1 dual agonists50, dual SGLT1/SGLT2 inhibitors51, G protein–coupled receptor (GPCR/GPR) agonists52, apical sodium-dependent bile acid transporter (ASBT) inhibitors53, chemokine receptor 2 and 5 antagonists, fibroblast growth factor 19 agonists54, and modulators of microbiota or their products among many others MetS treatment is an area under intense investigation.